Mr. Poltilove serves as an advisor, consultant, and independent Board Director, helping companies with fund-raising, commercialization, and inorganic growth strategies. Previously, as Operating Partner with BroadOak Capital Partners, Mr. Poltilove led the firm’s investment strategy in Cell and Gene Therapy, Bioproduction, and Cell Biology. Mr. Poltilove joined BroadOak after 12 years with Thermo Fisher Scientific where he served as Vice President and General Manager. Mr. Poltilove started up and led long-range strategy and day-to-day operations for the company’s cell and gene therapy business. He built a team that delivered 50%+ annual growth and championed the acquisition of Brammer Bio. Prior to Thermo Fisher, Mr. Poltilove served as Director of Revenue Strategy & Operations at the Corporate Executive Board and also held several commercial strategy roles with Johnson & Johnson. He holds Bachelor’s degrees in Chemical Engineering and Economics from the Massachusetts Institute of Technology as well as an MBA from the J.L. Kellogg School of Management at Northwestern University.